Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abstral conversion in breakthrough cancer pain
NCT01315886Phase 4Terminated
- Sponsor
- Orexo AB
- Start
- Feb 2011
- Primary completion
- Dec 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fentanyl in breakthrough cancer pain (BTcP), sponsored by Orexo AB. Primary endpoint: Response rate in patients converted to SL fentanyl. Started Feb 2011; status: terminated.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on NCT01315886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01315886.